The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer

Br J Cancer. 1986 Mar;53(3):331-7. doi: 10.1038/bjc.1986.56.

Abstract

A sensitive flow cytometric assay has been developed using a monoclonal antibody, Myc 1-6E10, to quantitate c-myc oncoprotein levels in nuclei isolated from wax embedded testicular tumours. The oncoprotein (p62c-myc) level increased significantly with increasing teratoma differentiation. Patients with intermediate and undifferentiated tumours who developed recurrence had lower p62c-myc levels than those who were disease free since their initial treatment. Such quantitative biochemical methods may provide new prognostic indices for cancer patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • Cell Transformation, Neoplastic
  • Flow Cytometry
  • Humans
  • Male
  • Neoplasm Proteins / biosynthesis*
  • Oncogenes*
  • Prognosis
  • Protein Biosynthesis*
  • Recurrence
  • Teratoma / genetics
  • Teratoma / metabolism
  • Testicular Neoplasms / genetics
  • Testicular Neoplasms / metabolism*

Substances

  • Antibodies, Monoclonal
  • Neoplasm Proteins